[go: up one dir, main page]

TN2009000324A1 - Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoides - Google Patents

Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoides

Info

Publication number
TN2009000324A1
TN2009000324A1 TNP2009000324A TN2009000324A TN2009000324A1 TN 2009000324 A1 TN2009000324 A1 TN 2009000324A1 TN P2009000324 A TNP2009000324 A TN P2009000324A TN 2009000324 A TN2009000324 A TN 2009000324A TN 2009000324 A1 TN2009000324 A1 TN 2009000324A1
Authority
TN
Tunisia
Prior art keywords
glucocorticoid receptor
modulators
tricyclic compounds
compounds
salts
Prior art date
Application number
TNP2009000324A
Other languages
English (en)
Inventor
Rajesh Venkateswaran Devraj
Crescenzo Gary A De
Xiao Hu
Kevin Dewayne Jerome
Mark Gerard Obukowicz
Lisa Olson
Paul Vincent Rucker
Ronald Keith Webber
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of TN2009000324A1 publication Critical patent/TN2009000324A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/58—Pyridine rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)

Abstract

La présente invention concerne des composés de formule I ou leurs sels, qui sont des modulateurs du récepteur de glucocorticoides . Les composés et sels de l'invention sont utiles dans le traitement d'affections à médiation par l'activité du récepteur de glucocorticoides.
TNP2009000324A 2007-02-02 2009-07-31 Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoides TN2009000324A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88798107P 2007-02-02 2007-02-02
PCT/IB2008/000229 WO2008093227A1 (fr) 2007-02-02 2008-01-25 Composés tricycliques et leur utilisation en tant que modulateurs des récepteurs des glucocorticoïdes

Publications (1)

Publication Number Publication Date
TN2009000324A1 true TN2009000324A1 (fr) 2010-12-31

Family

ID=39315208

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2009000324A TN2009000324A1 (fr) 2007-02-02 2009-07-31 Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoides

Country Status (42)

Country Link
US (7) US7598231B2 (fr)
EP (1) EP2114970B1 (fr)
JP (1) JP4599462B2 (fr)
KR (2) KR101107949B1 (fr)
CN (2) CN101616925B (fr)
AP (1) AP2455A (fr)
AR (2) AR065134A1 (fr)
AT (1) ATE518872T1 (fr)
AU (1) AU2008211613B2 (fr)
BR (1) BRPI0808634A2 (fr)
CA (1) CA2676670C (fr)
CL (2) CL2008000330A1 (fr)
CO (2) CO6190603A2 (fr)
CR (2) CR10948A (fr)
CU (2) CU23824A3 (fr)
CY (2) CY1110962T1 (fr)
DK (1) DK2114970T3 (fr)
DO (1) DOP2009000190A (fr)
EA (1) EA016494B1 (fr)
EC (2) ECSP099552A (fr)
ES (2) ES2368286T3 (fr)
GE (2) GEP20125404B (fr)
GT (2) GT200900210A (fr)
HN (2) HN2008000179A (fr)
HR (1) HRP20110702T1 (fr)
IL (1) IL199972A (fr)
MA (2) MA31117B1 (fr)
MX (1) MX2009008284A (fr)
MY (3) MY153057A (fr)
NI (2) NI200900149A (fr)
NZ (1) NZ578638A (fr)
PE (2) PE20081736A1 (fr)
PL (1) PL2114970T3 (fr)
PT (2) PT2114970E (fr)
RS (2) RS51970B (fr)
SI (1) SI2114970T1 (fr)
SV (2) SV2009003346A (fr)
TN (1) TN2009000324A1 (fr)
TW (2) TWI347842B (fr)
UA (2) UA94639C2 (fr)
WO (1) WO2008093227A1 (fr)
ZA (2) ZA200906064B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU714980B2 (en) 1996-07-24 2000-01-13 Warner-Lambert Company Llc Isobutylgaba and its derivatives for the treatment of pain
MY153057A (en) * 2007-02-02 2014-12-31 Pfizer Prod Inc Tryclic compounds,compositions and methods
NZ590559A (en) * 2008-07-28 2011-09-30 Pfizer Phenanthrenone compounds, compositions and methods
US8765787B2 (en) * 2008-11-21 2014-07-01 Bridge Pharma, Inc. Methods of treatment of xerophthalmia with self-preserving ocular formulations of norketotifen
US20100136097A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100135983A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-inflammatory compositions and methods
US20100136096A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100137247A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-inflammatory compositions and methods
US20100136094A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100136095A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100137246A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-inflammatory compositions and methods
JP2013526514A (ja) 2010-05-10 2013-06-24 ラディカル・セラピューティックス・インコーポレイテッド リポ酸およびニトロキシド誘導体およびその使用
SG187909A1 (en) * 2010-08-27 2013-03-28 Corcept Therapeutics Inc Pyridyl-amine fused azadecalin modulators
EP2685821A4 (fr) * 2011-03-15 2014-08-20 Abbvie Inc Modulateurs des récepteurs hormonaux nucléaires
US8545904B1 (en) 2012-06-05 2013-10-01 Liquid Innovators, LLC Topical composition containing Carapa (andiroba) oil for psoriasis and other related dermatological disorders
US9227901B2 (en) * 2012-07-05 2016-01-05 Abbvie Inc. Process for preparing bicyclic amine derivatives
TW201422590A (zh) 2012-09-07 2014-06-16 Abbvie Inc 雜環核激素受體調節劑
EP2935284A4 (fr) 2012-12-21 2016-04-27 Abbvie Inc Modulateurs hétérocycliques des récepteurs nucléaires aux hormones
CA2947303C (fr) 2014-05-16 2020-06-16 Liqwd, Inc. Compositions de traitement de la keratine et procedes associes
WO2016064759A1 (fr) * 2014-10-20 2016-04-28 Oyster Point Pharma, Inc. Méthodes de traitement de troubles oculaires
CN104591988A (zh) * 2014-12-29 2015-05-06 甘肃省化工研究院 6-溴-2-萘满酮的合成方法
WO2016149756A1 (fr) * 2015-03-23 2016-09-29 The University Of Melbourne Traitement de maladies respiratoires
SG11201808650QA (en) 2016-04-07 2018-10-30 Oyster Point Pharma Inc Methods of treating ocular conditions
US20220281846A1 (en) 2018-11-07 2022-09-08 The University Of Melbourne Compounds and compositions for the treatment of respiratory diseases

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2576025B1 (fr) 1985-01-14 1987-01-23 Roussel Uclaf Nouveaux steroides substitues en position 10, leur procede et les intermediaires de preparation, leur application comme medicaments, les compositions pharmaceutiques les contenant
FR2600450B1 (fr) * 1986-06-19 1988-08-26 Pechiney Aluminium Procede de marquage individuel des anodes precuites pour la production electrolytique d'aluminium
GB9518953D0 (en) * 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
IL122740A (en) 1997-01-15 2003-09-17 Akzo Nobel Nv 16-hydroxy-11-(substituted phenyl)-estra-9,4-diene derivatives, their preparation and pharmaceutical compositions containing them
EP1175383B1 (fr) * 1999-04-30 2018-03-14 Pfizer Products Inc. Glucocorticoide recepteur modulateurs
US6544781B1 (en) 1999-07-15 2003-04-08 The General Hospital Corporation Non-defective Epstein-Barr viral vector
IL146057A (en) * 2000-10-27 2007-09-20 Pfizer Prod Inc A process for the preparation of modulators of a non-steroidal glucocorticoid receptor
JP2002193911A (ja) * 2000-10-28 2002-07-10 Pfizer Prod Inc グルココルチコイドレセプターモジュレーター
ATE303369T1 (de) * 2000-10-30 2005-09-15 Pfizer Prod Inc Glucocorticoid rezeptor modulatoren
CN1474995A (zh) * 2000-11-20 2004-02-11 �����ι�˾ 射频识别标志与磁盘驱动器的连接
AU2002309172A1 (en) 2001-06-22 2003-01-08 Pfizer Products Inc. Pharmaceutical compositions containing polymer and drug assemblies
WO2003020216A1 (fr) 2001-08-31 2003-03-13 Corcept Therapeutics, Inc. Methodes d'inhibition de la deterioration cognitive chez des adultes atteints du syndrome de down
WO2003029217A2 (fr) 2001-09-27 2003-04-10 Universite De Liege Derives de sulfonamide pyridinique, procede de fabrication et d'utilisation
DE10164366C1 (de) * 2001-12-28 2003-06-05 Rehau Ag & Co Permanentkathode
ATE395044T1 (de) 2002-02-01 2008-05-15 Pfizer Prod Inc Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien
WO2004004653A2 (fr) 2002-07-02 2004-01-15 Corcept Therapeutics, Inc. Methodes de traitement de la psychose associee a une therapie aux interferon $g(a)
MXPA05000345A (es) * 2002-07-08 2005-03-31 Pfizer Prod Inc Moduladores del receptor de glucocorticoides.
EP1581234A4 (fr) 2002-11-05 2007-09-12 Corcept Therapeutics Inc Procédés pour traiter la migraine
US20040229855A1 (en) 2003-02-04 2004-11-18 Corcept Therapeutics, Inc. Antiglucocorticoids for the treatment of postpartum psychosis
US20050080061A1 (en) 2003-07-23 2005-04-14 Corcept Therapeutics, Inc. Antiglucocorticoid therapy for the prevention of neurological damage in premature infants
US8097606B2 (en) 2003-07-23 2012-01-17 Corcept Therapeutics, Inc. Antiglucocorticoids for the treatment of catatonia
TW200512181A (en) 2003-09-26 2005-04-01 Tanabe Seiyaku Co Amide-type carboxamide derivatives
ES2398239T3 (es) * 2003-11-10 2013-03-14 The Scripps Research Institute Composiciones y procedimientos para inducir la desdiferenciación celular
JP2007511501A (ja) * 2003-11-13 2007-05-10 ファイザー・プロダクツ・インク グルココルチコイド受容体調節剤として有用なオクタヒドロフェナンスレンヒドラジド誘導体
TWI370129B (en) 2005-02-14 2012-08-11 Msd Oss Bv Non steroidal glucocorticoid receptor modulators
AU2007248059A1 (en) 2006-05-02 2007-11-15 Corcept Therapeutics, Inc. The use of a glucocorticoid receptor ii antagonist to treat depression in patients taking il-2
NZ578661A (en) * 2007-02-02 2010-12-24 Pfizer Prod Inc Tricyclic compounds and their use as glucocorticoid receptor modulators
MY153057A (en) * 2007-02-02 2014-12-31 Pfizer Prod Inc Tryclic compounds,compositions and methods

Also Published As

Publication number Publication date
ZA200906064B (en) 2010-05-26
US20120095062A1 (en) 2012-04-19
TWI373466B (en) 2012-10-01
EP2114970B1 (fr) 2011-08-03
US8445520B2 (en) 2013-05-21
CO6220937A2 (es) 2010-11-19
TW200838514A (en) 2008-10-01
US20080188443A1 (en) 2008-08-07
MX2009008284A (es) 2009-08-12
CA2676670A1 (fr) 2008-08-07
AU2008211613B2 (en) 2013-05-23
EA016494B1 (ru) 2012-05-30
ES2368286T3 (es) 2011-11-16
CY1111758T1 (el) 2015-10-07
US20140316139A1 (en) 2014-10-23
CR10948A (es) 2009-08-07
EA200970666A1 (ru) 2010-02-26
HK1135108A1 (en) 2010-05-28
RS51970B (en) 2012-02-29
CY1110962T1 (el) 2015-06-11
US7547714B2 (en) 2009-06-16
CU20090133A7 (es) 2011-10-31
NI200900148A (es) 2010-02-15
GEP20125404B (en) 2012-02-27
CA2676670C (fr) 2012-03-13
GT200900210A (es) 2010-04-05
CL2008000330A1 (es) 2008-08-08
GEP20125426B (en) 2012-03-26
AR065134A1 (es) 2009-05-20
MY153057A (en) 2014-12-31
US20080312294A1 (en) 2008-12-18
US7598231B2 (en) 2009-10-06
MY148780A (en) 2013-05-31
IL199972A (en) 2013-09-30
SI2114970T1 (sl) 2011-11-30
US20100286214A1 (en) 2010-11-11
ATE518872T1 (de) 2011-08-15
DOP2009000190A (es) 2009-08-31
AP2009004942A0 (en) 2009-08-31
NI200900149A (es) 2010-02-15
PT2114888E (pt) 2011-01-04
AU2008211613A1 (en) 2008-08-07
GT200900209A (es) 2010-07-22
UA95332C2 (uk) 2011-07-25
KR101114682B1 (ko) 2012-03-14
US7786097B2 (en) 2010-08-31
MA31117B1 (fr) 2010-01-04
BRPI0808634A2 (pt) 2014-08-05
DK2114970T3 (da) 2011-09-19
ES2353822T3 (es) 2011-03-07
CU23848B1 (es) 2012-10-15
CU23824A3 (es) 2011-10-31
CN101616896B (zh) 2012-07-04
US8901310B2 (en) 2014-12-02
PL2114970T3 (pl) 2011-11-30
UA94639C2 (ru) 2011-05-25
ECSP099553A (es) 2009-08-28
KR20090108115A (ko) 2009-10-14
US8158660B2 (en) 2012-04-17
PT2114970E (pt) 2011-09-22
RS51646B (en) 2011-10-31
PE20081736A1 (es) 2008-11-28
US20140142316A1 (en) 2014-05-22
KR101107949B1 (ko) 2012-02-08
SV2009003349A (es) 2010-04-13
US20090281148A1 (en) 2009-11-12
EP2114970A1 (fr) 2009-11-11
TW200846325A (en) 2008-12-01
CN101616896A (zh) 2009-12-30
CO6190603A2 (es) 2010-08-19
MY146087A (en) 2012-06-29
MA31158B1 (fr) 2010-02-01
US20120088802A9 (en) 2012-04-12
WO2008093227A1 (fr) 2008-08-07
AP2455A (en) 2012-08-31
HN2008000179A (es) 2010-06-09
NZ578638A (en) 2010-12-24
CU20090132A7 (es) 2011-10-14
KR20090107080A (ko) 2009-10-12
AR065135A1 (es) 2009-05-20
CR10949A (es) 2009-08-07
JP2010517990A (ja) 2010-05-27
JP4599462B2 (ja) 2010-12-15
ECSP099552A (es) 2009-08-28
ZA200906060B (en) 2010-05-26
TWI347842B (en) 2011-09-01
IL199972A0 (en) 2010-04-15
SV2009003346A (es) 2010-04-13
CL2008000329A1 (es) 2008-08-08
PE20090113A1 (es) 2009-02-13
HN2008000178A (es) 2011-02-25
HRP20110702T1 (hr) 2011-10-31
CN101616925A (zh) 2009-12-30
CN101616925B (zh) 2012-05-23

Similar Documents

Publication Publication Date Title
TN2009000324A1 (fr) Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoides
MA31906B1 (fr) Inhibiteurs de la replication du virus de limmunodeficience humaine
MA34650B1 (fr) Antagonistes du récepteur cgrp de pipéridinone carboxamide azaindane
MA34474B1 (fr) Agonistes de gpr40
MA38380A1 (fr) Inhibiteurs quinazoline de l'activation des formes mutantes du récepteur de croissance épidermique (egfr)
MA33492B1 (fr) Inhibiteurs de bace
MA33334B1 (fr) Derives de l-(piperidine-4-yl)-pyrazole servant de modulateurs de gpr 119
MA33155B1 (fr) Composes organiques et leurs utilisations
WO2009069032A3 (fr) Nouveaux agonistes des récepteurs des glucocorticoïdes
MA32035B1 (fr) Composes tricycliques servant de modulateurs de synthese de tnf-alpha et d'inhibiteurs de pde4
EA200602243A1 (ru) 3-аминоциклопентанкарбоксамиды в качестве модуляторов хемокиновых рецепторов
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
MA31521B1 (fr) Dérivés de 2,3-dihydrobenzo[1,4] dioxin-2-ylméthyle utilisés en tant qu'antagonistes des alpha2c pour traiter des maladies des systèmes nerveux périphérique et central
MA34545B1 (fr) Co-cristaux et sels d'inhibiteurs de ccr3
MA38315B1 (fr) Composés tétracycliques substitués par un hétérocycle et procédés pour les utiliser pour le traitement de maladies virales
TW200734323A (en) 3-Aminocyclopentanecarboxamides as modulators of chemokine receptors
EA200602242A1 (ru) 3-аминоциклопентанкарбоксамиды в качестве модуляторов хемокиновых рецепторов
MA32282B1 (fr) Dérivés de 2-phényl-pyridine substitués
EP2563794A4 (fr) Inhibiteurs de l'activité protéine tyrosine kinase et leurs applications au traitement de troubles ophtalmiques
MA35893B1 (fr) Dérivés d'amide hétérocyclique comme antagonistes du récepteur p2x7
MA33242B1 (fr) Composes pour le traitement de troubles metaboliques
MA37691B1 (fr) 5-amino[1,4]thiazines comme inhibiteurs de bace1
EA200970662A1 (ru) Трициклические соединения и их применение в качестве модуляторов глюкокортикоидного рецептора
MA32158B1 (fr) Thiazolyldihydroindazoles
MA39253A1 (fr) Composés hétéroaryle bicycliques substitués utilisés comme agonistes de rxr